Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography

Cardiovascular Ultrasound

Volumn 5, Issue , 2007, Pages

  Galderisi, Maurizio ^a   Marra, Francesco ^a   Esposito, Roberta ^a   Lomoriello, Vincenzo Schiano ^a   Pardo, Moira ^a   De Divitiis, Oreste ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE; ARSENIC TRIOXIDE; BEVACIZUMAB; BRAIN NATRIURETIC PEPTIDE; BUSULFAN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IMATINIB; INTERLEUKIN 2; MITOMYCIN; PACLITAXEL; RETINOIC ACID; RITUXIMAB; THALIDOMIDE; TRASTUZUMAB; TROPONIN I; TROPONIN T; UNINDEXED DRUG; VINCA ALKALOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANGINA PECTORIS; ARTICLE; BRADYCARDIA; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DIAGNOSTIC VALUE; DOPPLER ECHOCARDIOGRAPHY; DRUG FEVER; DYSPNEA; ELECTROCARDIOGRAM; ENDOCARDITIS; ESOPHAGUS CANCER; FLUID RETENTION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HOLTER MONITORING; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTENSION; HYPOKINESIA; HYPOTENSION; KIDNEY CARCINOMA; LOEFFLER ENDOCARDITIS; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; METASTASIS; MYOCARDITIS; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PERICARDIAL EFFUSION; PERICARDITIS; PLEURA EFFUSION; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; QUALITY OF LIFE; RADIATION INJURY; RADIODIAGNOSIS; RADIOISOTOPE VENTRICULOGRAPHY; SEMINOMA; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; STRESS ECHOCARDIOGRAPHY; TESTIS TUMOR; THROMBOEMBOLISM; THROMBOSIS; THYMOMA; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

ANTINEOPLASTIC AGENTS; ECHOCARDIOGRAPHY, DOPPLER; HEART DISEASES; HUMANS; IMAGE ENHANCEMENT; NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY;

EID: 33846920629     PISSN: None     EISSN: 14767120     Source Type: Journal    
DOI: 10.1186/1476-7120-5-4     Document Type: Article

References (99)

1. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. JW Mason MR Bristow ME Billingham JR Daniels, Cancer Treat Rep 1978 62 857 864 667859
2. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. D Cardinale MT Sandri A Colombo N Colombo M Boeri G Lamantia M Civelli F Peccatori G Martinelli C Fiorentini CM Cipolla, Circulation 2004 109 2749 2754 10.1161/01.CIR.0000130926.51766.CC 15148277
3. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. SE Lipshultz N Rifai SE Sallan SR Lipsitz V Dalton DB Sacks ME Ottlinger, Circulation 1997 96 2496 2497 9355882
4. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. AS Maisel J Koon P Krishnaswamy R Kazenegra P Clopton N Gardetto R Morrisey A Garcia A Chiu A De Maria, Am Heart J 2001 141 367 374 10.1067/mhj.2001.113215 11231433
5. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. T Nousiainen E Jantunen E Vanninen J Remes O Vuolteenaho J Hartikainen, Eur J Haematol 1999 62 135 141 10052718
6. Reporting results of cancer treatment. AB Miller B Hoogstraten M Staquet A Winkler, Cancer 1981 47 207 214 10.1002/1097-0142(19810101)47:1<207::AID- CNCR2820470134>3.0.CO;2-6 7459811
7. Role of iron in anthracycline action. C Myers, "Organ Directed Toxicities of Anticancer Drugs" Boston Mass: Martinus Nijhoff, Hacker M, Lazo J, Tritton T, 1988 17 30
8. The natural history of anthracycline cardiotoxicity in children. MK Ali, "Cancer Treatment and the Patient" Baltimore, Md: The John Hopkins University, Muggia F, 1992 246 255
9. Cyclophoshamide cardiotoxicity in bone marrow transplantation.: a prospective evaluation of new dosing regimens. AC Braverman JH Antin MT Plappert EF Cook RT Lee, J Clin Oncol 1991 10 995 1000
10. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. E Dow H Schulman E Agura, Bone Marrow Transplant 1993 12 169 172 8401367
11. Cardiotoxicity associated with high-dose cyclophosphamide therapy. JS Gottdiener FR Appelbaum VJ Ferrans A Deisseroth J Ziegler, Arch Intern Med 1981 141 758 763 10.1001/archinte.141.6.758 7235784
12. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. MT Meinardi JA Gietema WT van der Graaf DJ van Veldhuisen MA Runne WJ Sluiter EG de Vries PB Willemse NH Mulder MP van den Berg HS Koops DT Sleijfer, J Clin Oncol 2000 18 1725 1732 10764433
13. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. N Frickhofen FJ Beck B Jung HG Fuhr H Andrasch M Sigmund, Ann Oncol 2002 13 797 801 10.1093/annonc/mdf035 12075751
14. Coronary vasospasm as a cause of effort-related myocardial ischemia during low dose chronic continuous infusion of 5-fluorouracil. C Lestuzzi E Viei E Picano N Meneguzzi, Am J Med 2001 111 316 318 10.1016/S0002-9343(01)00808-7 11566462
15. Thrombosis with paclitaxel. P Sevelda K Mayerhofer A Obermair J Stolzlechner C Kurz, Lancet 1994 343 727 731 10.1016/S0140-6736(94)91602-0 7907689
16. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. US Kammula DE White SA Rosenberg, Cancer 1998 83 797 805 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2- M 9708948
17. The "retinoic acid syndrome" in acute promyelocitic leukemia. SR Frankel A Eardley G Lauwers M Weiss RP Warrell Jr, Ann Intern Med 1992 117 292 296 1637024
18. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. MS Tallman JW Andersen CA Schiffer FR Appelbaum JH Feusner A Ogden L Shepherd JM Rowe C Francois RS Larson PH Wiernik, Blood 2000 95 90 95 10607690
19. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. SL Soignet, Oncologist 2001 Suppl 2 11 16 10.1634/theoncologist.6- suppl_2-11
20. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. H Kantarjian C Sawyers A Hochhaus F Guilhot C Schiffer C Gambacorti-Passerini D Niederwieser D Resta R Capdeville U Zoellner M Talpaz B Druker J Goldman SG O'Brien N Russell T Fischer O Ottmann P Cony-Makhoul T Facon R Stone C Miller M Tallman R Brown M Schuster T Loughran A Gratwohl F Mandelli G Saglio M Lazzarino D Russo M Baccarani E Morra for the International STI571 CML Study Group, N Engl J Med 2002 346 645 652 10.1056/NEJMoa011573 11870241
21. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma. MH Cohen LE Broder BE Fossieck DC Ihde JD Minna, Cancer Treat Rep 1977 61 489 490 194694
22. Monoclonal antibodies in the treatment of cancer, part 2. RJ Cersosimo, Am J Health Syst Pharm 2003 60 1631 1641 12966906
23. Clinical cardiac tolerability of trastuzumab. EA Perez R Rodeheffer, J Clin Oncol 2004 22 322 329 10.1200/JCO.2004.01.120 14722042
24. Textbook of radiotherapy, radiation physics, therapy and oncology. J Walter H Miller CK Bomford IH Kunkler Walter Millers eds, Edinburgh: Churchill Livingstone 2002
25. Cardiovascular emergencies in the cancer patient. D Keefe, Semin Oncol 2000 27 244 55 10864214
26. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. F Orzan A Brusca MR Conte P Presbitero MC Figliomeni, Br Heart J 1993 69 496 500 8343315
27. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. JP Veinot WD Edwards, Hum Pathol 1996 27 766 773 10.1016/S0046-8177(96)90447-5 8760008
28. Echocardiographic abnormalities following cardiac radiation. DJ Perrault M Levy JD Herman RJ Burns BZ Bar Shlomo MN Druck WQ Wu PR McLaughlin BW Gilbert, J Clin Oncol 1985 3 546 551 3981225
29. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease. S Pohjola-Sintonen KJ Totterman M Salmo P Siltanen, Cancer 1987 60 31 37 10.1002/1097-0142(19870701)60:1<31::AID-CNCR2820600107>3.0. CO;2-D 3581032
30. Endothelins: a possible mechanism of cytostatics-induced cardiomyopathy. A Zsary S Szucs K Keltai T Schneider A Rosta P Sarman T Fenyvesi I Karadi, Leuk Lymphoma 2004 45 351 355 10.1080/10428190310001593607 15101723
31. In vitro studies on the chemotherapeutics. I Low-Friederich F von Bredow W Schoeppe, Chemotherapy 1990 36 416 421 2292204
32. The in-vitro effect of antineoplastic agents on proliferative activity and cytoskeletal components of plaque-derived smooth-muscle cells from human coronary arteries. R Voisard PC Dar4tsch U Seitzer A Hannekum D Roth M Kochs V Hombach, Coronary Artery Dis 1993 4 935 942
33. Gamma-irradiation modulates vascular smooth muscle cell and extracellular matrix function: Implications for neointimal development. J Heckenkamp GR Nigri PR Waterman M Overhaus SC Kossodo GM Lamuraglia, J Vasc Surg 2004 39 1097 1103 10.1016/j.jvs.2003.12.021 15111867
34. Anthracycline-induced cardiotoxicity. K Shan AM Lincoff JB Young, Ann Intern Med 1996 125 47 58 8644988
35. Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin. E Hrovatin E Viel C Lestuzzi L Tartuferi F Zardo M Brieda E Dametto R Piazza F Antonini-Canterin E Vaccher N Meneguzzo GL Nicolosi, J Cardiovasc Med 2006 7 637 640
36. Cardiotoxicity of the antiproliferative compound fluorouracil. K Becker JF Erckenbrecht D Haussinger T Frieling, Drugs 1999 57 475 484 10.2165/00003495-199957040-00003 10235688
37. Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. D Schechter A Nagler A Ackerstein H Nassar D Admon E Naparstek AJ Rein, Cardiology 1992 80 168 171 1511464
38. Coronary artery spasm induced by capecitabine. A Sestito GA Sgueglia C Pozzo A Cassano C Barone F Crea GA Lanza, J Cardiovascv Med 2006 7 136 138
39. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. K Ohnishi H Yoshida K Shigeno S Nakamura S Fujisawa K Naito K Shinjo Y Fujita H Matsui A Takeshita S Sugiyama H Satoh H Terada R Ohno, Ann Intern Med 2001 133 881 885
40. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. H Nakamae K Tsumura M Hino T Hayashi N Tatsumi, Lancet 2000 355 805 806 10.1016/S0140-6736(00)02051-1 10711930
41. Presence of prolonged dispersion of qt intervals in late survivors of childhood anthracycline therapy. M Gupta HT Thaler L Steinherz, Pediatr Hematol Oncol 2002 19 533 542 10.1080/08880010290097387 12487828
42. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. MS Ewer SM Lippman, J Clin Oncol 2005 23 2900 2902 10.1200/JCO.2005.05. 827 15860848
43. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. MR Zile CF Baicu WH Gaasch, N Engl J Med 2004 350 1953 1959 10.1056/NEJMoa032566 15128895
44. Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin's Lymphoma Study Group. J Krupicka J Markova D Pohlreich T Kozak H Linkova V Diehl, Leuk Lymphoma 2002 43 2325 2329 12613519
45. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. B Marchandise E Schroeder A Bosly C Doyen P Weynants R Kremer H Pouleur, Am Heart J 1989 118 92 98 10.1016/0002-8703(89)90077-X 2741800
46. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. G Tjeerdsma MT Meinardi WT van Der Graaf MP van Den Berg NH Mulder HJ Crijns EG de Vries DJ van Veldhuisen, Heart 1999 81 419 423 10092570
47. Cardiac diastolic function in pediatric patients receiving doxorubicin. MS Ewer MK Ali HR Gibbs J Swafford KL Graff A Cangir N Jaffe MK Thapar, Acta Oncol 1994 33 645 649 7946442
48. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. D Iarussi M Galderisi G Ratti MA Tedesco P Indolfi F Casale MT Di Tullio O de Divitiis A Iacono, Clin Cardiol 2001 24 663 669 11594412
49. Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. B Ocal D Oguz S Karademir D Birgen N Yuksek U ertem F Cabuk, Pediatr Cardiol 2002 23 522 527 12211201
50. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. K Sorensen GA Levitt C Bull I Dorup ID Sullivan, Cancer 2003 97 1991 1998 10.1002/cncr.11274 12673729
51. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. P Morandi PA Ruffini GM Benvenuto L La Vecchia G Mezzena R Raimondi, Bone Marrow Transplant 2001 28 277 282 10.1038/sj.bmt.1703132 11535996
52. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. E Baldini T Prochilo B Salvadori A Bolognesi D Aldrighetti M Venturini R Rosso F Carnino L Gallo P Giannessi PF Conte C Orlandini P Bruzzi, Br J Cancer 2004 91 45 49 10.1038/sj.bjc.6601883 15173858
53. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. WH Kruit KJ Punt SH Goey PH de Mulder DC van Hoogenhuyze SC Henzen-Logmans G Stoter, Cancer 1994 74 2850 2856 10.1002/1097-0142(19941115)74: 10<2850::AID-CNCR2820741018>3.0.CO;2-T 7954247
54. Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogenic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration. SK Sohn JG Kim DH Kim KB Lee, Br J Hematol 2003 121 469 472 10.1046/j.1365-2141. 2003.04288.x
55. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. B Rotoli L Catalano M Galderisi L Luciano G Pollio A Guerriero A D'Errico C Mecucci R La Starza F Frigeri R Di Francia A Pinto, Leuk Limphoma 2004 45 2503 2507 10.1080/10428190400002293
56. Echocardiographic abnormalities following cardiac radiation. DJ Perrault M Levy JD Herman RJ Burns BZ Bar Shlomo MN Druck WQ Wu PR McLaughlin BW Gilbert, J Clin Oncol 1985 3 546 551 3981225
57. Diastolic dysfunction after mediastinal irradiation. PA Heidenreich SL Hancock RH Vagelos BK Lee I Schnittger, Am Heart J 2005 150 977 982 10.1016/j.ahj.2004.12.026 16290974
58. Asymptomatic cardiac disease following mediastinal irradiation. PA Heidenreich SL Hancock BK Lee CS Mariscal I Schnittger, J Am Coll Cardiol 2003 42 750 751 10.1016/S0735-1097(03)00759-9 12932614
59. Mitral regurgitation after anthracycline treatment for childhood malignancy. J Allen JD Thomson IJ Lewis JL Gibbs, Heart 2001 85 430 432 10.1136/heart.85.4.430 11250971
60. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. MB Lund H Ihlen BM Voss AF Abrahamsen O Nome J Kongerud M Stugaard K Forfang, Heart 1996 75 591 596 8697163
61. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. MC Hull CG Morris CJ Pepine NP Mendenhall, JAMA 2003 290 2831 2837 10.1001/jama.290.21.2831 14657067
62. Cardiac morbidity of adjuvant radiotherapy for breast cancer. DA Patt JS Goodwin YF Kuo JL Freeman DD Zhang TA Buchholz GN Hortobagyi SH Giordano, J Clin Oncol 2005 23 7475 7482 10.1200/JCO.2005.13.755 16157933
63. Echocardiographic features of radiation-associated valvular disease. D Hering L Faber D Horstkotte, Am J Cardiol 2003 92 226 230 10.1016/S0002-9149(03) 00546-0 12860232
64. Pericardial.disease in the oncology patient. AS Retter, Heart Dis 2002 4 387 391 10.1097/00132580-200211000-00008 12441016
65. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996. H Dazzi K Kaufmann F Follath, Ann Oncol 2001 12 963 966 10.1023/A:1011196910325 11521803
66. Cardiac complications of radiation therapy. AM Gaya RF Ashford, Clin Oncol 2005 17 153 159 10.1016/j.clon.2004.09.016
67. Cardiac complications of mediastinal radiotherapy. The other side of the coin. BF Byrd 3rd LA Mendes, J Am Coll Cardiol 2003 42 750 751 10.1016/S0735-1097(03)00760-5 12932614
68. Radiation induced heart disease: a study of twenty-five patients. JR Stewart KE Cohn LF Fajardo EW Hancock HS Kaplan, Radiology 1967 89 302 310
69. The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin's disease. MM Applefeld JF Cole SH Pollock FJ Sutton RG Slawson RT Singleton PH Wiernik, Ann Intern Med 1981 94 338 341 7224379
70. Delayed appearance of effusive-constrictive pericarditis after radiation for Hodgkin lymphoma. GC Kane RN Edie JD Mannion, Ann Intern Med 1996 124 435 436
71. Echocardiography in the diagnosis and management of pericardial disease. M Pepi M Muratori, J Cardiovasc Med 2006 7 533 544
72. Sensitivity and specificity of echocardiographic diagnosis of pericardial effusion. M Hortowitz C Scultz E Stinson, Circulation 1974 50 239 247 4846631
73. Asymptomatic carotid arterial disease in young patients following neck radiation therapy for Hodgkin lymphoma. LJ King SN Hasnain JA Webb JE Kingston EA Shafford TA Lister J Shamash RH Reznek, Radiology 1999 213 167 172 10540657
74. Clinical manifestations of non coronary atherosclerotic vascular disease after moderate dose irradiation. DA Patel J Kochanski AW Suen LF Fajardo SL Hancock SJ Knox, Cancer 2006 106 718 725 10.1002/cncr.21636 16353211
75. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. DC Bowers DE McNeil Y Liu Y Yasui M Stovall JG Gurney MM Hudson SS Donaldson RJ Packer PA Mitby CE Kasper LL Robison KC Oeffinger, J Clin Oncol 2005 23 6508 6515 10.1200/JCO.2005.15.107 16170160
76. Doppler echocardiography during follow-up ofthe hematological patients undergoing chemotherapy. F Marra M Galderisi A Camera CR Rinaldi P Innelli B Rotoli O de Divitiis, Int J Cardiol
77. Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. M Bountioukos JK Doorduijn JR Roelandt EC Vourvouri JJ Bax AF Schinkel MD Kertai P Sonneveld D Poldermans, Eur J Echocardiogr 2003 4 300 305 10.1016/S1525-2167(03)00017-9 14611826
78. Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Y Cottin I L'huillier O Casasnovas C Geoffroy D Caillot M Zeller E Solary H Guy JE Wolf, Eur J Echocardiogr 2000 1 180 183 10.1053/euje.2000. 0037 11916591
79. Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. L Lanzarini G Bossi ML Laudisa C Klersy M Arico, Am Heart J 2000 140 315 323 10.1067/mhj.2000.108237 10925349
80. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. SE Klewer SJ Goldberg RL Donnerstein RA Berg JJ Hutter Jr, J Am Coll Cardiol 1992 19 394 401 1732369
81. Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. H Hamada T Ohkubo M Maeda S Ogawa, Pediatr Int 2006 48 313 320 10.1111/j.1442-200X.2006.02210.x 16732801
82. Ultrasonic backscatter and collagen in normal ventricular myocardium. RM Hoyt DJ Skorton SM Collins HE Melton Jr, Circulation 1984 69 775 782 6697461
83. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. E Picano G Pelosi M Marzilli F Lattanzi A Benassi L Landini A L'Abbate, Circulation 1990 81 58 64 2404628
84. Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. V Di Bello L Talarico E Picano C Di Muro L Landini M Paterni E Matteucci C Giusti O Giampietro, J Am Coll Cardiol 1995 25 1408 1415 10.1016/0735-1097(95)00026-Z 7722141
85. A new perspective on cardiotoxicity of 5-fluorouracil. A novel research tool 'cardiac ultrasonic integrated backscatter analysis' indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen. S Barutca C Ceyhan N Meydan B Ozturk T Tekten A Onbasili G Kadikoylu Z Bolaman, Chemotherapy 2004 50 113 118 10.1159/000077884 15272225
86. The variation of integrated backscatter in human hearts in differing ultrasonic transthoracic views. A Lange CM Moran P Palka LN Fenn GR Sutherland WN McDicken, J Am Soc Echocardiogr 1995 8 830 838 10.1016/S0894-7317(05)80007-0 8611283
87. Ultrasonic analysis of anthracycline-induced myocardial damage using cyclic variation of integrated backscatter. H Nagai W Omi T Yuasa S Sakagami S Takata K Kobayashi, J Am Soc Echocardiogr 2003 16 808 813 10.1067/S0894-7317(03) 00425-5 12878989
88. What are we actually measuring by Doppler tissue imaging? K Isaaz, J Am Coll Cardiol 2000 36 897 899 10.1016/S0735-1097(00)00800-7 10987617
89. Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. M Wang GW Yip AY Wang Y Zhang PY Ho MK Tse PK Lam JE Sanderson, J Am Coll Cardiol 2003 41 820 826 10.1016/S0735-1097(02)02921-2 12628728
90. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. SR Ommen RA Nishimura CP Appleton FA Miller JK Oh MM Redfield AJ Tajik, Circulation 2000 102 1788 1794 11023933
91. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. S Tassan-Mangina D Codorean M Metivier B Costa C Himberlin C Jouannaud AM Blaise J Elaerts P Nazeyrollas, Eur J Echocardiogr 2006 7 141 146 10.1016/j.euje.2005.04.009 15941672
92. Value of pulsed Doppler tissue imaging for early detection of myocardial dysfunction with anthracyclines. S Tassan-Mangina C Brasselet P Nazeyrollas M Collot-Bigot B Costa AM Blaise P Laury L Bonfils D Metz J Elaerts, Arch Mal Coeur Vaiss 2002 95 263 268 12055764
93. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. L Kapusta JM Thijssen J Groot-Loonen T Antonius J Mulder O Daniels, Ultrasound Med Biol 2000 26 1099 1108 10.1016/S0301-5629(00)00252-0 11053744
94. The comet-tail artifact. An ultrasound sign of alveolar-interstitial syndrome. D Lichtenstein G Meziere P Biderman A Gepner O Barre, Am J Respir Crit Care Med 1997 156 1640 1646 9372688
95. A lung ultrasound sign allowing bedside distinction between pulmonary edema and COPD: the comet-tail artifact. D Lichtenstein G Meziere, Intensive Care Med 1998 24 1331 1334 10.1007/s001340050771 9885889
96. Ultrasound lung comets: a clinically useful sign of extravascular lung water. E Picano F Frassi E Agricola S Gligorova L Gargani G Mottola, J Am Soc Echocardiogr 2006 19 356 363 10.1016/j.echo.2005.05.019 16500505
97. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? MT Sandri M Salvatici D Cardinale L Zorzino R Passerini P Lentati M Leon M Civelli G Martinelli CM Cipolla, Clin Chem 2005 51 1405 1410 10.1373/clinchem.2005.050153 15932966
98. Interstitial lung disease associated with drug therapy. B Camus S Kudoh M Ebina, Cancer 2004 Suppl 2 S18 S23
99. Serial HRCT lung change after 3-field radiation treatment of breast cancer. GC Ooi DL Kwong KN Chan H Ngan DT Lock WK Lam FL Chan G Au KW Tsang, Clin Radiol 2000 55 817 824 10.1053/crad.2000.0542 11069735